Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YH001 + envafolimab + doxorubicin
- Development stage
- Unknown
- Lead developer
- TRACON Pharmaceuticals
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
**YH001 + envafolimab + doxorubicin** is an investigational combination therapy targeting front-line treatment of common sarcoma subtypes (leiomyosarcoma, dedifferentiated liposarcoma). YH001 is a humanized IgG1 monoclonal antibody targeting CTLA-4, designed to enhance T-cell activation and anti-tumor immune response, with augmented antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) relative to ipilimumab. Envafolimab (KN035) is a novel, subcutaneously injectable, recombinant humanized single-domain anti-PD-L1 antibody fused to the Fc domain of IgG1, facilitating blockade of the PD-1/PD-L1 pathway for immune checkpoint inhibition. Doxorubicin is a chemotherapeutic agent (anthracycline antibiotic) that inhibits topoisomerase II and intercalates DNA, resulting in cytotoxicity. The triplet therapy seeks synergistic anti-tumor effects by combining immune checkpoint inhibition with cytotoxic chemotherapy.
- Other names
- YH001 + envafolimab + doxorubicinYH001 + KN035 + doxorubicin
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on YH001 + envafolimab + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YH001 + envafolimab + doxorubicin.